Fig. 4
MSC-CM delivery ameliorates TAA-stimulated FHF and CCl4-stimulated liver fibrosis. a Schema depicting MSC-CM treatment for FHF. b Schema depicting MSC-CM treatment for chronic liver fibrosis. c Kaplan–Meier survival analysis of mice with TAA-induced FHF. d MSC-CM treatment substantially improved the gross histopathological appearance of TAA-stimulated livers. e, f Fibrosis and necroinflammatory scores were determined using the scoring system of Ishak for CCl4-stimulated livers. Quantification of (g) α-SMA-, (h) Ki67-, and (i) TUNEL-positivity. j HE staining of liver sections from control and MSC-CM-treated TAA-stimulated livers. k Necroinflammatory scores determined by Necroinflammatory score system of Ishak in TAA-stimulated livers. l Sirius red, m HE, n α-SMA immunofluorescence, o Ki67 immunofluorecence, p TUNEL staining of liver sections from CCl4-stimulated all group. Data are shown as mean ± standard error of the mean of 10 random high-power fields per mouse.*P < 0.05; **P < 0.01; ***P < 0.001